RESUMO
Background: Lung cancer is the main cause of cancer deaths worldwide. Around 1.8 million people are diagnosed worldwide with lung cancer each year. This accounts for about 13% of total cancer diagnoses making it the most common cancer disease. Lung cancer is also the type of cancer that has the highest mortality, killing approximately 1.6 million people annually. The highest incidence rates among men are in the United States and Eastern Europe, whereas the highest among women are in North America and Northern Europe
Aim of the Work: The aim of this study is to analyze the importance of clinicopathological parameters and treatment modality as prognostic factors affecting survival of patients diagnosed as Non small cell lung cancer [NSCLC] and the quality of life
Methods: We retrospectively reviewed the clinical records of patients with inoperable stage III/IV NSCLC, who were treated at the department of Clinical Oncology, Ain Shams University Hospital and the International Medical center between 2009 and 2017. The association between the demographic and clinical characteristics and survival of these patients was analyzed
Results: A total of 69 patients [32 stage III and 39 stage IV] were identified and included in this study. Sex [males vs. females, p=0.04], Eastern cooperative Oncology group performance status [0 vs. 1 vs. 2, p=0.001], smoking habit [never vs. current vs. former, p=0.001], stage [IIIA vs. IIIB vs. IV, p=0.008] and the initial treatment [no vs. chemotherapy vs. concurrent chemoradiotherapy, p=0.001] were found to be factors affecting survival in univariate analyses. Sex and histological subtype did not affect survival. Performance status, stage and initial treatment were determined as the independent prognostic factors affecting survival in multivariate analyses
Conclusion: Performance status, stage and initial treatment with concurrent chemoradiotherapy in eligible patients were prognostic factors affecting overall survival of patients with advanced NSCLC
RESUMO
To evaluate the outcome of concomitant radiocemotherapy [RCT] in terms of treatment response, tolerability, possibility of subsequent surgical resection and survival in locally advanced pancreatic carcinoma. Twenty patients with locally advanced pancreatic carcinoma had been included in a prospective study. Patients had attended to Kas El Aini Center of Clinical Oncology and to the Menoufiya University Hospital and Liver institute, between September 1998 and December 2000. All patients were treated by RCT compirising 5400 cGy daily fractions of180 cGy 5 days a week, 5-Floruracil [5-FU] : 600mg/m2 by continuous intravenous infusion day 1-day 5 and Mitomycin-C': 10mg/m[2], i.v.-bolus day 2. Chemotherapy was repeated on day 29. patients were re-evaluated for the treatment outcome and the possibility of surgical resection 4 weeks after RCT Treatment response, toxicity and overall survival were the study end point. Twelve patients [60%] had decreased primary tumor size. Five cases appeared potentially respectable by CT and exp1plorative laparotomies were done but only four could be respected. The median survival of the study group was 10 months [range 4-21]. Themedian survival of patients who had undergone surgery was 19 ms [1421] response but appeared irresistible by the CT scan. The mediam survival of patients with stationary or progressive tumors was 6.5 ms [4-10]. The treatment applied in the study is feasible and have o significant acute toxicity. The respectability was improved but with no improvement of survival. Additional neoadjuvanl chemotherapy trials with new regimens may support the potential benefits of this line of treatmen